Anne-Marie Masquelier joins Cegedim Strategic Data

Takes role of global medical research director

Cegedim Strategic Data (CSD), a French provider of integrated healthcare research, has appointed Dr Anne-Marie Masquelier as global medical research director of its medical research CRO activities worldwide.

Masquelier is a medical doctor MD with a specialisation in endocrinology and holds an MBA in marketing/management. She started her career as a medical practitioner before moving to the healthcare industry where she held various management positions in pharmaceutical, CRO and biotech companies. Most recently she was general manager of Genethon.

Masquelier will manage CSD’s established medical research teams in France, Germany, Italy, Spain and UK, China, Japan and the US. She will continue the expansion of this activity in all of the 39 countries where CSD is present.

You may also like

Regulatory

Power to the patient: The value of longitudinal data

Steve Bradley, Group Managing Director, Cegedim UK, outlines how data holds the key to better patient care
Finance

Cegedim Dendrite forms partnership with TAKE Solutions

Arrangement will enable Cegedim to expand its presence in India
Finance

Cegedim expands business in Switzerland

Acquires Swiss CRM and Direct Marketing businesses of IMS Health
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Subscribe now